Domača stran9VC • ETR
add
ATAI Life Sciences NV
Prejšnji trg. dan.
1,21 €
Dnevni razpon
1,22 € - 1,27 €
Letni razpon
0,93 € - 2,50 €
Tržna kapitalizacija
292,50 mio. USD
Povprečni obseg
1,60 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | dec. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | −5,00 tis. | −127,78 % |
Stroški poslovanja | 29,34 mio. | −12,62 % |
Čisti dohodek | −38,96 mio. | −112,98 % |
Čista dobičkovnost prihodkov | 779,16 tis. | 866,72 % |
Earnings per share | −0,24 | −100,00 % |
EBITDA | −29,12 mio. | 12,97 % |
Efektivna davčna stopnja | 1,81 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | dec. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 62,33 mio. | −65,23 % |
Skupna sredstva | 159,39 mio. | −45,69 % |
Skupne obveznosti | 42,83 mio. | −12,87 % |
Celoten lastniški kapital | 116,55 mio. | — |
Shares outstanding | 198,31 mio. | — |
Razmerje P/B | 1,75 | — |
Donosnost sredstev | −41,11 % | — |
Donosnost kapitala | −46,44 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | dec. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −38,96 mio. | −112,98 % |
Denar iz dejavnosti | −24,30 mio. | −10,62 % |
Denar iz naložb | 6,56 mio. | 897,08 % |
Denar iz financiranja | 154,00 tis. | 101,82 % |
Neto sprememba denarnih sredstev | −17,46 mio. | 44,50 % |
Prost denarni tok | −1,72 mio. | 86,74 % |
Vizitka
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Generalni direktor
Datum ustanovitve
2018
Spletno mesto
Zaposleni
54
